BIS-TRIMETHYLBENZOYL PHENYLPHOSPHINE OXIDE
Bis-Trimethylbenzoyl Phenylphosphine Oxide is the organic compound.
製品には実際どれくらい入っているか
この成分の含有量を表示した製品はまだありません。
この成分を含む製品のうち7件は全成分の前の方（1%ラインより前）、0件は後ろ（ふつう1%以下）に書いています。
この成分を含む製品
確認済み 7件中 7件 · 十分に入っている製品から
定義
米国FDA 物質登録 · UNII JOV61FMS35 · 登録名 BIS-TRIMETHYLBENZOYL PHENYLPHOSPHINE OXIDE · 単一の化学物質
Bis-Trimethylbenzoyl Phenylphosphine Oxide is the organic compound.
化粧品での役割
安全性・規制情報
韓国の有害物質GHS分類なし · 既存化学物質
CIR reviewed this ingredient and flagged its status as: Insufficient Data Announcement: Safety Assessment of Bis Trimethylbenzoyl PhenylphosphineOxide, Ethyl Trimethylbenzoyl Phenylphosphinate, andTrimethylbenzoyl Diphenylphosphine Oxide (insufficient data or use not supported — CIR's own classification, not a full safety-as-used conclusion).
出典: 米国CIR 安全性評価
詳しい資料 — 表示名・識別番号・物性・試験記録・文献
公式表示名・定義
日本化粧品工業会の表示名称 ビストリメチルベンゾイルフェニルホスフィンオキシド: 本品は、次の化学式で表される有機化合物である。
出典: 日本化粧品工業会 表示名称
別名・識別情報
- CAS No.化学物質登録番号
- 162881-26-7
- DTXSID米国EPA化学物質番号
- DTXSID8044597
- DTXCID米国EPA化合物番号
- DTXCID6024597
- IUPAC
- Phenylbis(2,4,6-trimethylbenzoyl)-lambda~5~-phosphanone
- 分子式
- C26H27O3P
- 分子量
- 418.473 g/mol
製品が実際に使っている用途
米国EPAにこの成分を届け出た製品13件の用途です。化粧品以外の製品も含まれるため、上の数行がこの成分の主な使い道といえます。
- Photosensitizers6
- Processing aids not otherwise specified3
- Photosensitive agent2
- Catalyst1
- Stabilizing agent1
出典: 米国EPA CompTox
刺激・感作試験の記録
皮膚試験15件・眼試験5件の記録があります。
試験の結論はおおむね一致しています（100%）。 原料そのものを試験した記録で、完成品に含まれる濃度での刺激性とは異なります。
試験20件をすべて見る
- Skin Sens. 1
Skin Sensitization · Authoritative - High Frequency of Sensitization
skin sensitisation: in vivo (non-LLNA) · Screening · according to other guideline: 92/69/EEC (maximisation), B.6 - High Frequency of Sensitization
skin sensitisation: in vivo (non-LLNA) · Screening · according to other guideline: 92/69/EEC (maximisation) - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · EU Method B.4 (Acute Toxicity: Dermal Irritation / Corrosion) (92/69/EEC) according to - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · other guideline: 92/69/EEC, B.4 according to - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · other guideline: 92/69/EEC according to - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · EU Method B.4 (Acute Toxicity: Dermal Irritation / Corrosion) (Directive 92/69/EEC) according to - Studies Indicate No Significant Irritation
skin irritation: in vivo · Screening · EU Method B.4 (Acute Toxicity: Dermal Irritation / Corrosion) according to - High Frequency of Sensitization
skin sensitisation: in vivo (non-LLNA) · Screening · according to EU Method B.6 (Skin Sensitisation) - High Frequency of Sensitization
skin sensitisation: in vivo (non-LLNA) · Screening · according to other guideline: 92/69/EEC (Maximisation) - Ambiguous
skin sensitisation: in vivo (non-LLNA) · Screening · according to other guideline: 92/69/EEC - High Frequency of Sensitization
skin sensitisation: in vivo (non-LLNA) · Screening · according to OECD Guideline 406 (Skin Sensitisation) (1992) - High Frequency of Sensitization
skin sensitisation: in vivo (non-LLNA) · Screening · according to EU Method B.6 (Skin Sensitisation) (Directive 92/69/EEC) - Ambiguous
skin sensitisation · Screening · according to other guideline: 92/69/EEC (Maximisation) - Category 6.5B (Category 1)
Skin Sensitization · Read Across - Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · other guideline: 92/69/EEC according to - Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · EU Method B.5 (Acute Toxicity: Eye Irritation / Corrosion) (92/69/EEC) according to - Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · EU Method B.5 (Acute Toxicity: Eye Irritation / Corrosion) (Directive 92/69/EEC) according to - Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · EU Method B.5 (Acute Toxicity: Eye Irritation / Corrosion) according to - Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · other guideline: 92/69/EEC, B.5 according to
出典: 米国EPA CompTox